Balyasny Asset Management
TEVA icon

Balyasny Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Balyasny Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,600
Closed -$6.01M – 3512
2025
Q4 		$6.01M Buy
192,600
+135,400
+237% +$3.34M 0.01% 1297
2025
Q3 		$1.16M Buy
+57,200
New +$1M ﹤0.01% 2056
2025
Q1 		– Sell
-53,300
Closed -$1.17M – 3275
2024
Q4 		$1.17M Sell
53,300
-42,500
-44% -$773K ﹤0.01% 1879
2024
Q3 		$1.73M Buy
+95,800
New +$1.68M ﹤0.01% 1732
2018
Q3 		– Sell
-695,000
Closed -$16.9M – 2031
2018
Q2 		$16.9M Buy
+695,000
New +$14.2M 0.08% 351
2018
Q1 		– Sell
-700,000
Closed -$13.3M – 2301
2017
Q4 		$13.3M Buy
700,000
+500,000
+250% +$7.52M 0.04% 548
2017
Q3 		$3.52M Buy
+200,000
New +$4.5M 0.01% 821
2016
Q2 		– Sell
-340,000
Closed -$18.2M – 1441
2016
Q1 		$18.2M Buy
+340,000
New +$19.9M 0.11% 267

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's TEVA Position: Q2 2025 in Review

Balyasny Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 28,613 shares — an estimated $440K sold.

Balyasny Asset Management first reported a position in TEVA in Q2 2013 and held it in 31 quarters. The position peaked at $223M in Q4 2015. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Balyasny Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 28,613 Teva Pharmaceuticals shares in Q2 2025, an estimated $440K.
  • Balyasny Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Balyasny Asset Management's Teva Pharmaceuticals position peaked at $223M in Q4 2015.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.